Anti-Cancer Compounds Targeted to VDAC: Potential and Perspectives

Area of Science:

• Mitochondrial biology
• Cancer research
• Pharmacology

Background:

• Voltage-Dependent Anion selective Channel (VDAC) proteins are pore-forming proteins in the outer mitochondrial membrane.
• VDACs play roles in bioenergetics, apoptosis, and the Warburg effect, linking mitochondrial metabolism to cytosolic functions.
• VDAC1 is implicated in cancer due to its involvement in key cellular processes like Hexokinase binding and the Warburg effect.

Purpose of the Study:

• To survey literature on drug compounds targeting cancer proliferation via VDAC.
• To categorize compounds based on their mechanism of action on VDAC.
• To explore the potential of VDAC as a pharmacological target in oncology.

Main Methods:

• Literature review of drug compounds acting on VDAC in cancer.
• Categorization of compounds into three main groups: VDAC-Hexokinase binding inhibitors, VDAC conductance inhibitors, and VDAC gene expression modulators.
• Inclusion of biological peptides as potential therapeutic agents.

Main Results:

• Identified drug compounds acting on VDAC-Hexokinase binding.
• Identified drug compounds directly inhibiting VDAC conductance.
• Identified drug compounds affecting VDAC gene expression levels.

Conclusions:

• VDAC is a promising, yet underexplored, pharmacological target for cancer therapy.
• Further research into VDAC's functional properties is needed to fully exploit its therapeutic potential.
• Targeting VDAC offers a novel strategy in the fight against cancer.